AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Daily Turnover | The turnover of Align Technology on 9/5 was $146.14 Million, Ranking 691
ByAinvest
Friday, Sep 5, 2025 6:00 pm ET1min read
The turnover of Align Technology on 9/5/2025 was $146.14 million, ranking 691 in today's market, the Volume is 1.06 million.
Align Technology(ALGN) shares closed at $139.12, up 3.28% on 9/5/2025, down 2.00% in the last 5 trading days, down 2.00% this month, down 33.28% year-to-date and down 37.09% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 9/5/2025 | $146.14 million | 1.06 million | $139.12 | 3.28% |
| 9/4/2025 | $170.17 million | 1.27 million | $134.7 | 1.77% |
| 9/3/2025 | $233.01 million | 1.75 million | $132.355 | -3.50% |
| 9/2/2025 | $159.79 million | 1.17 million | $137.16 | -3.38% |
| 8/29/2025 | $139.51 million | 0.98 million | $141.96 | 0.59% |
【Company Profile】
Align Technology, Inc. was founded in March 1997 and incorporated in Delaware in April 1997. Align is a global medical device company primarily engaged in the design, manufacture and marketing of Invisalign clear aligners for the treatment of malocclusions, or the misalignment of teeth, by orthodontists and general dental practitioners, ViveraTM retainers for retention, iTeroTM intraoral scanners and services for dentistry, and exocadTM computer-aided design and computer-aided manufacturing software for dental laboratories and dental practitioners. The company vision and strategy is to revolutionize orthodontic and restorative dentistry through digital treatment planning and implementation using Align Digital PlatformTM, an integrated suite of proprietary technologies and services designed to deliver a seamless, end-to-end solution for patients, consumers, orthodontists, GPs and lab partners.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet